Supported by a prestigious Steering Committee, the MedFIT conference programme features the latest opinions on trending topics related to collaborative innovation partnerships and focuses on market access, financing, the digitalisation of the sector and regulations.
How to increase the number of MedTech unicorns in Europe?
Europe is currently benefiting from a dynamic MedTech start-up ecosystem. However, not so many of these start-ups succeed in scaling-up. What are the possible strategies and paths to get bigger on MedTech market in Europe? What do we lack in order to accompany the scaling-up of MedTech companies? How to grow the private equity and stock markets to enable more frequent success in that process? How to ensure that the development and consolidation of the sector are also fuelled by MedTech SMEs merger and acquisition deals?
TRACK 1: COLLABORATE TO INNOVATE
Faster together: Which recent trends in academia-big players collaborations?
The shifting MedTech landscape has led big industry players to seek new collaborations to support their R&D needs rather than in-house efforts, initiating fresh ways to partner with academic institutions and speeding-up market access. On which needs are these collaborations focusing and what are the main reasons driving big players to partner with academia? To what extent are academia and industry developing common frameworks, protocols and processes to enable efficient collaboration?
Big size vs mid-size companies: Different ways to deal with early-stage start-ups?
Start-ups with new medical technology on the market are becoming overpriced. Therefore, large and mid-size companies are showing a growing interest for earlier stage MedTech companies through R&D collaboration and licensing deals when looking outside for new R&D. Which strategies are those companies pursuing? Is there a difference of pattern between big and mid-size companies approaches when dealing with early stage investment and assets?
What are the key factors of success in the relationship between an academic institution and a resulting spin-off?
Networking opportunities, use of laboratories and research cooperation are key resources universities can provide to their spin-offs in their further development. How can these ventures make their academic institution of origin a long-term partner? Which benefits do universities have when continuing to provide the start-up with the support required? Are there some ideal routines and guidelines to create a profitable and long-lasting collaboration for both?
TRACK 2: FINANCING INNOVATION
How are healthcare systems and health plans directly investing in innovative companies in Europe?
Healthcare systems and health plans have been a growing source of innovation investment and their interest in financing start-up companies and new technologies appears to be at its peak. Facing a twofold challenge to improve patient care while cutting costs, which assets are healthcare systems and health plans targeting? Is this ad-hoc innovation investment or can we observe more permanent and strategic approaches?
Co-founder & Partner
Health Program Director AXA Next
AXA GROUP INNOVATION TEAM
Director MedTech Consulting and Business Development
HEALTH ENTERPRISE EAST
Co-Founder & CEO
DIABETES DIGITAL MEDIA
How will moving toward outcome-based payment models affect financing in MedTech?
Moving toward value-based care models, MedTech companies have seen increasing price pressures and the necessity to improve patient outcomes. When it comes to demonstrate the improvements in patient outcomes, it may prove longer for a company to see significant financial return. How are the new outcome-based payment models changing the way innovation is perceived? How is quality measured and how are investment criteria evolving? Who takes on risk in a value-based care model? How to ensure improved communication within the payers‘ community to ease funding and reimbursement?
Agnostic investors or pure players in the MedTech sector: Who is becoming prominent in the early-stage financing scene?
Seed and Series A investments are critical to transforming new ideas into products and moving start-up teams into small businesses. From investors with a varied degree of specialisation to totally agnostic players only focusing on MedTech, who are the main players at these financing stages? What is the significance of the amount of earlystage investment today for cross-industry funds, specialised healthcare funds and pure players in the MedTech industry respectively?
TRACK 3: MARKET INNOVATION
European Public Procurement and Innovation in MedTech : What are the strategies and best practices to facilitate purchasing and adoption of innovative medical technologies ?
A large part of Europe’s medical technologies are purchased using procurement processes. EU’s 2014 Public Procurement Directives introduced a number of changes in the European legal framework, including a focus on the role of public procurement in achieving innovation as well as good-practice examples on reducing administrative procedures, adjusting selection criteria, mobilising innovation brokers and designing an SME-friendly payment scheme to better attract innovators to public procurement.
This roundtable discussion will bring together public institutions, policymakers and innovative companies to provide a comprehensive overview of initiatives and good practices to foster and support public procurement of innovations.
Final stretch to MDR/IVDR implementation: How are companies revising their strategy to comply with the key requirements and associated timelines?
EU new regulations are introducing an enhanced framework around the definition, supervision, traceability and risk-based classification system for medical device equipment. They will shortly apply after a transitional period: May 2020 for the medical devices and May 2022 for in-vitro diagnostic medical devices. How has the upcoming deadline impacted the MedTech and diagnostic players both from a European point of view and for foreign companies conducting business in Europe? What long term implications may this new legislation have on innovation and market investment? How are companies and regulatory authorities dealing with the remaining uncertainties?
Shifting to value-based care models: What are the challenges for the diagnostic tests and technologies?
Health systems worldwide move from treatment to prevention, and from volumebased to value-based care model: Diagnostics can deliver significant improvements eased by the huge opportunities offered by digitalisation. As diagnostic services are a pivotal stage in patient care, early diagnosis can increase the probabilities of a positive outcome for patients and save costs of further treatment. How are the diagnostic providers aligning with value-based care? From diagnostic imaging to companion diagnostics, this panel discussion will explore the key challenges and share best practices for this strategic industry of the shifting healthcare system.
TRACK 4: DIGITAL INNOVATION
Connected devices redesign healthcare: How are MedTech companies adapting to this new environment?
Digital health technology and services are fastly growing, offering a wide new range of connected devices, transforming and personalising the way care is delivered. Information and data generated by medical technologies, paired with the advances in AI should play a vital role in improving health outcomes and making health systems more efficient. How are innovative companies, large and small, adapting their business models? How do they deal with the flow of data and the legal and regulatory related issues?
MedTech & digital industry: Which grounds for collaboration?
The MedTech sector has been subject to a substantial transformation during the past decade due to the arrival of new digital technologies and is now facing a growing inspiration from digital disrupters and tech giants expanding their healthcare reach through mergers and acquisitions. As more collaboration and integration across companies and sectors will be a vital part of the next wave of innovation what are the recent trends in jointly developing cutting-edge medical devices technologies? To what extent are MedTech and digital industry working together to deliver new products and services for patients? Which collaborative models are emerging? What are the successful examples, benefits, limits and constraints to these collaborations?
How do IT tools contribute to accelerate the process of completing clinical trials in the MedTech sector?
Clinical data and evaluation of that clinical data is an explicitly defined legal requirement for medical devices. Solutions to fast-track market access may emerge from wearables and data analytics programs and allow a stronger and more efficient patient engagement and monitoring. What impact and scalability do these IT solutions have on the medical device clinical trial design? How are they integrated in the market access strategies of MedTech players?